Integral Ad Science Holding Corp. (Nasdaq: IAS), a leading global media measurement and optimization platform, today announced financial results for the third quarter ended September 30, 2023.
“We achieved strong results in the third quarter highlighted by 21% growth in optimization revenue and a 23% increase in measurement revenue. Social media revenue growth accelerated to 41% as we extended our global platform partnerships and increased customer adoption of our market leading products. We are raising our full year 2023 financial outlook based on our positive third quarter performance and business momentum in the fourth quarter,” said Lisa Utzschneider, CEO of IAS.
Third Quarter 2023 Financial Highlights
- Total revenue was $120.3 million, a 19% increase compared to $101.3 million in the prior-year period.
- Optimization revenue was $57.0 million, a 21% increase compared to $47.1 million in the prior-year period.
- Measurement revenue was $47.8 million, a 23% increase compared to $39.0 million in the prior-year period.
- Publisher revenue was $15.5 million compared to $15.3 million in the prior-year period.
- International revenue, excluding the Americas, was $36.9 million, a 17% increase compared to $31.6 million in the prior-year period, or 31% of total revenue for the third quarter of 2023.
- Gross profit was $94.7 million, a 15% increase compared to $82.2 million in the prior-year period. Gross profit margin was 79% for the third quarter of 2023.
- Net loss was $13.7 million, or $0.09 per share, compared to net income of $0.8 million, or $0.00 per share, in the prior-year-period. Net loss margin was 11% for the third quarter of 2023.
- Adjusted EBITDA* increased to $40.6 million, a 35% increase compared to $30.1 million in the prior-year period. Adjusted EBITDA* margin was 34% for the third quarter of 2023.
- Cash and cash equivalents were $92.2 million at September 30, 2023.
Recent Business Highlights
- TikTok Expansion – During the quarter, IAS continued to expand its Total Media Quality (TMQ) brand safety and suitability measurement product in TikTok. TMQ is now available to advertisers in more than 50 markets.
- YouTube Suitability Dashboard – Advertisers using IAS’s TMQ product on YouTube now have access to a suitability dashboard that allows them to analyze brand suitability trends and create a custom suitability profile.
- Google Campaign Manager Integration – IAS enhanced its integration with Google Campaign Manager 360. Marketers now have the ability to wrap tags, create, and launch campaigns with ease. This enhancement ensures advertiser data is automatically populated in IAS Signal and creates greater efficiencies and reduced campaign creation time.
- X Partnership – IAS announced an exclusive, first-to-market partnership with X to provide pre-bid brand safety and suitability across the social media platform. IAS leads the industry in providing end-to-end support for marketers on X with a full array of solutions from measurement to optimization.
- Instacart Partnership – IAS announced that it will provide viewability and invalid traffic (IVT) measurement on Instacart Ads, Instacart’s advertising products and solutions, which reaches more than 5,500 brands.
- Amazon DSP Integration – IAS enhanced its integration with Amazon Ads to include Context Control pre-bid segments. In addition to IAS’s standard pre-bid segments within Amazon’s DSP, customers can now easily discover and avoid unsuitable content and reach contextually relevant content.
- TrustArc Certification – IAS earned its first certification from TrustArc. The TRUSTe Enterprise Privacy seal certifies that IAS’s data privacy policies and practices align with the standards set by the leaders in governance and compliance.
Financial Outlook
“We are pleased with 19% revenue growth for the third quarter which reflects investments we have made in key business initiatives,” said Tania Secor, CFO of IAS. “We continue to prioritize profitable growth, and adjusted EBITDA margin expanded to 34% in the period. During the quarter, we paid down an additional $20 million in debt for a total of $50 million in debt reduction year-to-date. We look forward to executing on our strategy in the fourth quarter, our seasonally strongest period.”
IAS is introducing the following financial outlook for the fourth quarter of 2023 and increasing its full year 2023 outlook for revenue and adjusted EBITDA:
Fourth Quarter Ending December 31, 2023:
- Total revenue of $130 million to $132 million
- Adjusted EBITDA* of $45 million to $47 million
Year Ending December 31, 2023:
- Total revenue of $470 million to $472 million
- Adjusted EBITDA* of $157 million to $159 million
* See “Supplemental Disclosure Regarding Non-GAAP Financial Information” section herein for an explanation of these measures. IAS is unable to provide a reconciliation for forward-looking guidance of adjusted EBITDA and corresponding margin to net income (loss), the most closely comparable GAAP measures without unreasonable effort, because certain material reconciling items, such as depreciation and amortization, interest expense, income tax expense (benefit) and acquisition, restructuring and integration expenses, cannot be estimated due to factors outside of IAS’s control and could have a material impact on the reported results. However, IAS estimates stock-based compensation expense for the fourth quarter of 2023 in the range of $15 million to $16 million and for the full year 2023 in the range of $81 million to $82 million.
|
INTEGRAL AD SCIENCE HOLDING CORP. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
|
|||
|
(IN THOUSANDS, EXCEPT SHARE DATA) |
September 30, |
December 31, |
|
|
ASSETS |
|||
|
Current assets: |
|||
|
Cash and cash equivalents |
$ 92,248 |
$ 86,877 |
|
|
Restricted cash |
127 |
45 |
|
|
Accounts receivable, net |
86,682 |
67,884 |
|
|
Unbilled receivables |
41,857 |
41,550 |
|
|
Prepaid expenses and other current assets |
18,853 |
24,761 |
|
|
Due from related party |
20 |
29 |
|
|
Total current assets |
239,787 |
221,146 |
|
|
Property and equipment, net |
3,506 |
2,412 |
|
|
Internal use software, net |
36,079 |
23,642 |
|
|
Intangible assets, net |
188,402 |
217,558 |
|
|
Goodwill |
673,755 |
674,094 |
|
|
Operating lease right-of-use assets |
22,368 |
22,787 |
|
|
Deferred tax asset, net |
1,673 |
2,020 |
|
|
Other long-term assets |
4,705 |
5,024 |
|
|
Total assets |
$ 1,170,275 |
$ 1,168,683 |
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|||
|
Current liabilities: |
|||
|
Accounts payable and accrued expenses |
$ 59,748 |
$ 60,799 |
|
|
Due to related party |
38 |
122 |
|
|
Deferred revenue |
237 |
99 |
|
|
Operating lease liabilities, current |
9,031 |
6,749 |
|
|
Total current liabilities |
69,054 |
67,769 |
|
|
Net deferred tax liability |
24,371 |
45,495 |
|
|
Long-term debt |
173,609 |
223,262 |
|
|
Operating lease liabilities, non-current |
20,299 |
22,875 |
|
|
Other long-term liabilities |
4,296 |
1,066 |
|
|
Total liabilities |
291,629 |
360,467 |
|
|
Commitments and Contingencies (Note 13) |
|||
|
Stockholders’ Equity |
|||
|
Preferred Stock, $0.001 par value, 50,000,000 shares authorized at September 30, 2023; 0 shares issued and outstanding at September 30, 2023 and December 31, 2022. |
— |
— |
|
|
Common Stock, $0.001 par value, 500,000,000 shares authorized, 157,597,931 and 153,990,128 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively. |
158 |
154 |
|
|
Additional paid-in-capital |
883,386 |
810,186 |
|
|
Accumulated other comprehensive loss |
(3,688) |
(2,899) |
|
|
Retained earnings (accumulated deficit) |
(1,210) |
775 |
|
|
Total stockholders’ equity |
878,646 |
808,216 |
|
|
Total liabilities and stockholders’ equity |
$ 1,170,275 |
$ 1,168,683 |
|
|
INTEGRAL AD SCIENCE HOLDING CORP. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) |
||||||||
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||
|
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) |
2023 |
2022 |
2023 |
2022 |
||||
|
Revenue |
$ 120,331 |
$ 101,343 |
$ 340,074 |
$ 290,913 |
||||
|
Operating expenses: |
||||||||
|
Cost of revenue (excluding depreciation and amortization shown below) |
25,599 |
19,171 |
71,100 |
53,864 |
||||
|
Sales and marketing |
29,604 |
28,190 |
87,566 |
77,961 |
||||
|
Technology and development |
17,211 |
19,459 |
53,850 |
54,071 |
||||
|
General and administrative |
22,611 |
20,150 |
85,673 |
56,081 |
||||
|
Depreciation and amortization |
14,027 |
12,617 |
40,373 |
37,585 |
||||
|
Foreign exchange loss, net |
2,078 |
4,064 |
931 |
3,503 |
||||
|
Total operating expenses |
111,130 |
103,651 |
339,493 |
283,065 |
||||
|
Operating income (loss) |
9,201 |
(2,308) |
581 |
7,848 |
||||
|
Interest expense, net |
(3,109) |
(2,619) |
(9,747) |
(5,859) |
||||
|
Employee retention tax credit |
— |
6,981 |
— |
6,981 |
||||
|
Net income (loss) before income taxes |
6,092 |
2,054 |
(9,166) |
8,970 |
||||
|
Benefit (provision) from income taxes |
(19,841) |
(1,287) |
6,240 |
(5,083) |
||||
|
Net income (loss) |
$ (13,749) |
$ 767 |
$ (2,926) |
$ 3,887 |
||||
|
Net income (loss) per share: |
||||||||
|
Basic |
$ (0.09) |
$ 0.00 |
$ (0.02) |
$ 0.03 |
||||
|
Diluted |
$ (0.09) |
$ 0.00 |
$ (0.02) |
$ 0.02 |
||||
|
Weighted average shares outstanding: |
||||||||
|
Basic |
157,055,904 |
155,389,195 |
157,691,005 |
155,007,655 |
||||
|
Diluted |
157,055,904 |
156,696,754 |
157,691,005 |
157,581,569 |
||||
|
Other comprehensive loss: |
||||||||
|
Foreign currency translation adjustments |
(1,717) |
(3,248) |
(789) |
(11,218) |
||||
|
Total comprehensive loss |
$ (15,466) |
$ (2,481) |
$ (3,715) |
$ (7,331) |
||||
|
Stock-Based Compensation (UNAUDITED) |
|||||||
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
||||||
|
(IN THOUSANDS) |
2023 |
2022 |
2023 |
2022 |
|||
|
Cost of revenue |
$ 118 |
$ 101 |
$ 328 |
$ 258 |
|||
|
Sales and marketing |
5,714 |
4,457 |
17,859 |
10,650 |
|||
|
Technology and development |
2,902 |
3,168 |
13,434 |
6,979 |
|||
|
General and administrative |
5,166 |
6,521 |
34,020 |
15,220 |
|||
|
Total stock-based compensation |
$ 13,900 |
$ 14,247 |
$ 65,641 |
$ 33,107 |
|||
|
INTEGRAL AD SCIENCE HOLDING CORP. CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (UNAUDITED) |
||||||||||||
|
Three Months Ended September 30, 2023 |
||||||||||||
|
Common Stock |
||||||||||||
|
(IN THOUSANDS, EXCEPT SHARES) |
Shares |
Amount |
Additional paid-in capital |
Accumulated other comprehensive |
Retained |
Total stockholders’ equity |
||||||
|
Balance, July 1, 2023 |
156,279,075 |
$ 156 |
$ 867,490 |
$ (1,971) |
$ 12,539 |
$ 878,214 |
||||||
|
RSUs and MSUs vested |
1,102,702 |
1 |
— |
— |
— |
1 |
||||||
|
Option exercises |
53,748 |
1 |
590 |
— |
— |
591 |
||||||
|
ESPP purchase |
162,406 |
— |
1,424 |
— |
— |
1,424 |
||||||
|
Stock-based compensation |
— |
— |
13,882 |
— |
— |
13,882 |
||||||
|
Foreign currency translation adjustment |
— |
— |
— |
(1,717) |
— |
(1,717) |
||||||
|
Net loss |
— |
— |
— |
— |
(13,749) |
(13,749) |
||||||
|
Balance, September 30, 2023 |
157,597,931 |
$ 158 |
$ 883,386 |
$ (3,688) |
$ (1,210) |
$ 878,646 |
||||||
|
Nine Months Ended September 30, 2023 |
||||||||||||
|
Common Stock |
||||||||||||
|
(IN THOUSANDS, EXCEPT SHARES) |
Shares |
Amount |
Additional paid-in capital |
Accumulated other comprehensive |
Retained |
Total stockholders’ equity |
||||||
|
Balance, January 1, 2023 |
153,990,128 |
$ 154 |
$ 810,186 |
$ (2,899) |
$ 775 |
$ 808,216 |
||||||
|
RSUs and MSUs vested |
2,692,984 |
3 |
— |
— |
— |
3 |
||||||
|
Option exercises |
641,250 |
1 |
5,583 |
— |
— |
5,584 |
||||||
|
ESPP purchase |
273,569 |
— |
2,306 |
— |
— |
2,306 |
||||||
|
Stock-based compensation |
— |
— |
65,311 |
— |
— |
65,311 |
||||||
|
Foreign currency translation adjustment |
— |
— |
— |
(789) |
— |
(789) |
||||||
|
Adoption of ASC 326, net of tax |
— |
— |
— |
— |
941 |
941 |
||||||
|
Net loss |
— |
— |
— |
— |
(2,926) |
(2,926) |
||||||
|
Balance, September 30, 2023 |
157,597,931 |
$ 158 |
$ 883,386 |
$ (3,688) |
$ (1,210) |
$ 878,646 |
||||||
|
Three Months Ended September 30, 2022 |
||||||||||||
|
Common Stock |
||||||||||||
|
(IN THOUSANDS, EXCEPT SHARES) |
Shares |
Amount |
Additional paid-in capital |
Accumulated other comprehensive |
Accumulated deficit |
Total stockholders’ equity |
||||||
|
Balance, July 1, 2022 |
155,498,704 |
$ 155 |
$ 804,175 |
$ (8,285) |
$ (11,479) |
$ 784,566 |
||||||
|
RSUs vested |
471,995 |
— |
— |
— |
— |
— |
||||||
|
Option exercises |
603,670 |
1 |
2,526 |
— |
— |
2,527 |
||||||
|
Stock-based compensation |
— |
— |
14,225 |
— |
— |
14,225 |
||||||
|
Foreign currency translation adjustment |
— |
— |
— |
(3,248) |
— |
(3,248) |
||||||
|
Repurchase of common stock |
(3,080,061) |
(3) |
(23,652) |
— |
— |
(23,655) |
||||||
|
Net income |
— |
— |
— |
— |
767 |
767 |
||||||
|
Balance, September 30, 2022 |
153,494,308 |
$ 153 |
$ 797,274 |
$ (11,533) |
$ (10,711) |
$ 775,183 |
||||||
|
Nine Months Ended September 30, 2022 |
||||||||||||
|
Common Stock |
||||||||||||
|
(IN THOUSANDS, EXCEPT SHARES) |
Shares |
Amount |
Additional paid-in capital |
Accumulated other comprehensive |
Accumulated deficit |
Total stockholders’ equity |
||||||
|
Balance, January 1, 2022 |
154,398,495 |
$ 154 |
$ 781,951 |
$ (315) |
$ (14,600) |
$ 767,190 |
||||||
|
RSUs vested |
761,208 |
1 |
— |
— |
— |
1 |
||||||
|
Option exercises |
1,414,666 |
1 |
5,907 |
— |
— |
5,908 |
||||||
|
Stock-based compensation |
— |
— |
33,068 |
— |
— |
33,068 |
||||||
|
Foreign currency translation adjustment |
— |
— |
— |
(11,218) |
— |
(11,218) |
||||||
|
Repurchase of common stock |
(3,080,061) |
(3) |
(23,652) |
— |
— |
(23,655) |
||||||
|
Net income |
— |
— |
— |
— |
3,887 |
3,887 |
||||||
|
Balance, September 30, 2022 |
153,494,308 |
$ 153 |
$ 797,274 |
$ (11,533) |
$ (10,711) |
$ 775,183 |
||||||
|
INTEGRAL AD SCIENCE HOLDING CORP. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) |
||||
|
Nine Months Ended September 30, |
||||
|
(IN THOUSANDS) |
2023 |
2022 |
||
|
Cash flows from operating activities: |
||||
|
Net income (loss) |
$ (2,926) |
$ 3,887 |
||
|
Adjustments to reconcile net income (loss) to net cash provided by operating activities |
||||
|
Depreciation and amortization |
40,373 |
37,585 |
||
|
Stock-based compensation |
65,641 |
33,107 |
||
|
Foreign currency loss, net |
571 |
3,503 |
||
|
Deferred tax benefit |
(17,974) |
(657) |
||
|
Amortization of debt issuance costs |
348 |
348 |
||
|
Allowance for credit losses |
2,223 |
647 |
||
|
Employee retention tax credit |
— |
(6,981) |
||
|
Impairment of assets |
— |
55 |
||
|
Changes in operating assets and liabilities: |
||||
|
Increase in accounts receivable |
(19,936) |
(8,031) |
||
|
Increase in unbilled receivables |
(370) |
(289) |
||
|
Decrease (increase) in prepaid expenses and other current assets |
5,851 |
(6,757) |
||
|
Decrease (increase) in operating leases, net |
139 |
(502) |
||
|
Increase in other long-term assets |
(27) |
(330) |
||
|
Increase (decrease) in accounts payable and accrued expenses |
148 |
(8,226) |
||
|
Increase in deferred revenue |
150 |
127 |
||
|
Increase (decrease) in due to/from related party |
(93) |
74 |
||
|
Net cash provided by operating activities |
74,118 |
47,560 |
||
|
Cash flows from investing activities: |
||||
|
Payment for acquisitions, net of acquired cash |
— |
(1,603) |
||
|
Purchase of property and equipment |
(1,954) |
(917) |
||
|
Acquisition and development of internal use software and other |
(23,539) |
(9,952) |
||
|
Net cash used in investing activities |
(25,493) |
(12,472) |
||
|
Cash flows from financing activities: |
||||
|
Proceeds from the Revolver |
75,000 |
15,000 |
||
|
Repayment of long-term debt |
(125,000) |
(25,000) |
||
|
Repayment of short-term debt |
— |
(1,836) |
||
|
Proceeds from exercise of stock options |
5,584 |
5,908 |
||
|
Payments for repurchase of common stock |
— |
(23,655) |
||
|
Cash received from Employee Stock Purchase Program |
2,236 |
388 |
||
|
Net cash used in financing activities |
(42,180) |
(29,195) |
||
|
Net increase in cash, cash equivalents and restricted cash |
6,445 |
5,893 |
||
|
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
(1,330) |
(5,396) |
||
|
Cash, cash equivalents and restricted cash at beginning of period |
89,671 |
76,078 |
||
|
Cash, cash equivalents and restricted cash at end of period |
$ 94,786 |
$ 76,575 |
||
|
Supplemental Disclosures: |
||||
|
Cash paid during the period for: |
||||
|
Interest |
$ 8,880 |
$ 5,548 |
||
|
Taxes |
$ 10,361 |
$ 11,817 |
||
|
Non-cash investing and financing activities: |
||||
|
Property and equipment acquired included in accounts payable |
$ 17 |
$ 145 |
||
|
Internal use software acquired included in accounts payable |
$ 1,012 |
$ 1,385 |
||
|
Lease liabilities arising from right of use assets |
$ 29,330 |
$ 26,214 |
||
Supplemental Disclosure Regarding Non-GAAP Financial Information
We use supplemental measures of our performance, which are derived from our consolidated financial information, but which are not presented in our consolidated financial statements prepared in accordance with GAAP. Adjusted EBITDA is the primary financial performance measure used by management to evaluate our business and monitor ongoing results of operations. Adjusted EBITDA is defined as income before depreciation and amortization, stock-based compensation, interest expense, income taxes, acquisition, restructuring and integration costs, foreign exchange gain, net, asset impairments, and other one-time, non-recurring costs. Adjusted EBITDA margin represents the adjusted EBITDA for the applicable period divided by the revenue for that period presented in accordance with GAAP.
We use non-GAAP financial measures to supplement financial information presented on a GAAP basis. We believe that excluding certain items from our GAAP results allows management to better understand our consolidated financial performance from period to period and better project our future consolidated financial performance as forecasts are developed at a level of detail different from that used to prepare GAAP-based financial measures. Moreover, we believe these non-GAAP financial measures provide our shareholders with useful information to help them evaluate our operating results by facilitating an enhanced understanding of our operating performance and enabling them to make more meaningful period-to-period comparisons. Although we believe these measures are useful to investors and analysts for the same reasons they are useful to management, as discussed below, these measures are not a substitute for, or superior to, U.S. GAAP financial measures or disclosures. Our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.
Reconciliations of historical adjusted EBITDA to its most directly comparable GAAP financial measure, net income/loss, are presented below. We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. In future fiscal periods, we may exclude such items and may incur income and expenses similar to these excluded items.
|
Reconciliation of Adjusted EBITDA |
||||||||
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||
|
(IN THOUSANDS, EXCEPT PERCENTAGES) |
2023 |
2022 |
2023 |
2022 |
||||
|
Net income (loss) |
$ (13,749) |
$ 767 |
$ (2,926) |
$ 3,887 |
||||
|
Depreciation and amortization |
14,027 |
12,617 |
40,373 |
37,585 |
||||
|
Stock-based compensation |
13,900 |
14,247 |
65,641 |
33,107 |
||||
|
Interest expense, net |
3,109 |
2,619 |
9,747 |
5,859 |
||||
|
Provision (benefit) from income taxes |
19,841 |
1,287 |
(6,240) |
5,083 |
||||
|
Acquisition, restructuring and integration costs |
1,353 |
1,518 |
2,974 |
4,396 |
||||
|
Foreign exchange loss, net(1) |
2,078 |
4,064 |
931 |
3,551 |
||||
|
Employee retention tax credit |
— |
(6,981) |
— |
(6,981) |
||||
|
Asset impairments and other costs |
11 |
6 |
1,517 |
55 |
||||
|
Adjusted EBITDA |
$ 40,570 |
$ 30,144 |
$ 112,017 |
$ 86,542 |
||||
|
Revenue |
$ 120,331 |
$ 101,343 |
$ 340,074 |
$ 290,913 |
||||
|
Net income (loss) margin |
(11) % |
1 % |
(1) % |
1 % |
||||
|
Adjusted EBITDA margin |
34 % |
30 % |
33 % |
30 % |
||||
|
(1)The adjustment for foreign exchange loss, net, was effective for the three months ended June 30, 2022 and periods thereafter. Adjusted EBITDA has not been recast for this adjustment for periods prior to June 30, 2022, because such adjustments would have been immaterial in such periods. |
Conference Call and Webcast Information
IAS will host a conference call and live webcast to discuss its third quarter 2023 financial results today at 5:00 p.m. ET. To access the live webcast and conference call dial-in, please register under the “News & Events” section of IAS’s investor relations website. A replay will be available on IAS’s investor relations website following the live call: https://investors.integralads.com.
For more such updates, follow us on Google News Martech News